全文获取类型
收费全文 | 231976篇 |
免费 | 20440篇 |
国内免费 | 10862篇 |
专业分类
耳鼻咽喉 | 1253篇 |
儿科学 | 7832篇 |
妇产科学 | 4165篇 |
基础医学 | 28673篇 |
口腔科学 | 4359篇 |
临床医学 | 24314篇 |
内科学 | 45106篇 |
皮肤病学 | 2678篇 |
神经病学 | 13173篇 |
特种医学 | 5219篇 |
外国民族医学 | 62篇 |
外科学 | 17244篇 |
综合类 | 42943篇 |
现状与发展 | 41篇 |
一般理论 | 4篇 |
预防医学 | 14837篇 |
眼科学 | 4270篇 |
药学 | 20710篇 |
115篇 | |
中国医学 | 9322篇 |
肿瘤学 | 16958篇 |
出版年
2024年 | 203篇 |
2023年 | 2702篇 |
2022年 | 4434篇 |
2021年 | 7622篇 |
2020年 | 7665篇 |
2019年 | 6936篇 |
2018年 | 6689篇 |
2017年 | 7256篇 |
2016年 | 7692篇 |
2015年 | 7915篇 |
2014年 | 14094篇 |
2013年 | 16340篇 |
2012年 | 13797篇 |
2011年 | 15663篇 |
2010年 | 12824篇 |
2009年 | 12382篇 |
2008年 | 12845篇 |
2007年 | 13460篇 |
2006年 | 12239篇 |
2005年 | 11225篇 |
2004年 | 9533篇 |
2003年 | 8357篇 |
2002年 | 7166篇 |
2001年 | 6443篇 |
2000年 | 5393篇 |
1999年 | 4625篇 |
1998年 | 3746篇 |
1997年 | 3294篇 |
1996年 | 2670篇 |
1995年 | 2693篇 |
1994年 | 2345篇 |
1993年 | 1796篇 |
1992年 | 1594篇 |
1991年 | 1333篇 |
1990年 | 1181篇 |
1989年 | 959篇 |
1988年 | 755篇 |
1987年 | 660篇 |
1986年 | 591篇 |
1985年 | 783篇 |
1984年 | 634篇 |
1983年 | 401篇 |
1982年 | 525篇 |
1981年 | 374篇 |
1980年 | 325篇 |
1979年 | 242篇 |
1978年 | 210篇 |
1977年 | 165篇 |
1976年 | 152篇 |
1975年 | 111篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Rolf Svedjeholm Gabriele Ferrari Farkas Vanky Örjan Friberg Jonas Holm 《Acta anaesthesiologica Scandinavica》2023,67(10):1373-1382
Background
Glutamate plays a key role for post-ischaemic recovery of myocardial metabolism. According to post hoc analyses of the two GLUTAMICS trials, patients without diabetes benefit from glutamate with less myocardial dysfunction after coronary artery bypass surgery (CABG). Copeptin reflects activation of the Arginine Vasopressin system and is a reliable marker of heart failure but available studies in cardiac surgery are limited. We investigated whether glutamate infusion is associated with reduced postoperative rises of plasma Copeptin (p-Copeptin) after CABG.Methods
A prespecified randomised double-blind substudy of GLUTAMICS II. Patients had left ventricular ejection fraction ≤0.30 or EuroSCORE II ≥3.0 and underwent CABG ± valve procedure. Intravenous infusion of 0.125 M L-glutamic acid or saline at 1.65 mL/kg/h was commenced 10–20 min before the release of the aortic cross-clamp and then continued for another 150 min P-Copeptin was measured preoperatively and postoperatively on day one (POD1) and day three. The primary endpoint was an increase in p-Copeptin from the preoperative level to POD1. Postoperative stroke ≤24 h and mortality ≤30 days were safety outcomes.Results
We included 181 patients of whom 48% had diabetes. The incidence of postoperative mortality ≤30 days (0% vs. 2.1%; p = .50) and stroke ≤24 h (0% vs. 3.2%; p = .25) did not differ between the glutamate group and controls. P-Copeptin increased postoperatively with the highest values recorded on POD1 without significant inter-group differences. Among patients without diabetes, p-Copeptin did not differ preoperatively but postoperative rise from preoperative level to POD1 was significantly reduced in the glutamate group (73 ± 66 vs. 115 ± 102 pmol/L; p = .02). P-Copeptin was significantly lower in the Glutamate group on POD1 (p = .02) and POD 3 (p = .02).Conclusions
Glutamate did not reduce rises of p-Copeptin significantly after moderate to high-risk CABG. However, glutamate was associated with reduced rises of p-Copeptin among patients without diabetes. These results agree with previous observations suggesting that glutamate mitigates myocardial dysfunction after CABG in patients without diabetes. Given the exploratory nature of these findings, they need to be confirmed in future studies. 相似文献2.
3.
《The Journal of thoracic and cardiovascular surgery》2023,165(1):94-103.e24
ObjectiveNew-onset postoperative atrial fibrillation (POAF) after cardiac surgery is common, with rates up to 60%. POAF has been associated with early and late stroke, but its association with other cardiovascular outcomes is less known. The objective was to perform a meta-analysis of the studies reporting the association of POAF with perioperative and long-term outcomes in patients with cardiac surgery.MethodsWe performed a systematic review and a meta-analysis of studies that presented outcomes for cardiac surgery on the basis of the presence or absence of POAF. MEDLINE, EMBASE, and the Cochrane Library were assessed; 57 studies (246,340 patients) were selected. Perioperative mortality was the primary outcome. Inverse variance method and random model were performed. Leave-one-out analysis, subgroup analyses, and metaregression were conducted.ResultsPOAF was associated with perioperative mortality (odds ratio [OR], 1.92; 95% confidence interval [CI], 1.58-2.33), perioperative stroke (OR, 2.17; 95% CI, 1.90-2.49), perioperative myocardial infarction (OR, 1.28; 95% CI, 1.06-1.54), perioperative acute renal failure (OR, 2.74; 95% CI, 2.42-3.11), hospital (standardized mean difference, 0.80; 95% CI, 0.53-1.07) and intensive care unit stay (standardized mean difference, 0.55; 95% CI, 0.24-0.86), long-term mortality (incidence rate ratio [IRR], 1.54; 95% CI, 1.40-1.69), long-term stroke (IRR, 1.33; 95% CI, 1.21-1.46), and longstanding persistent atrial fibrillation (IRR, 4.73; 95% CI, 3.36-6.66).ConclusionsThe results suggest that POAF after cardiac surgery is associated with an increased occurrence of most short- and long-term cardiovascular adverse events. However, the causality of this association remains to be established. 相似文献
4.
《The Journal of thoracic and cardiovascular surgery》2023,165(2):622-629.e2
ObjectiveDeterioration of the native aortic valve function by a late progression of rheumatic disease is not infrequent in patients who underwent rheumatic mitral valve surgery; however, this phenomenon has not been clearly quantified.MethodsA total of 1155 consecutive patients (age 52.0 ± 12.9 years; 807 female) who underwent rheumatic mitral valve surgery without concomitant aortic valve surgery from 1997 to 2015 were enrolled. The primary end point was the composite of progression to severe aortic valve dysfunction or a requirement of subsequent aortic valve replacements during follow-up. To determine the risk factors of the primary outcome, we performed the generalized linear mixed model.ResultsThe baseline severities of aortic valve were none to trivial in 880 patients (76.2%), mild in 256 patients (22.2%), and moderate in 19 patients (1.6%). The latest 1062 echocardiographic assessments (91.9%; median, 81.2 postoperative months; interquartile range, 37.3-132.1 months) demonstrated 26 cases (0.33%/patient-year) meeting the primary end point during follow-up. Cumulative incidence of the primary end point at 10 years was 0.4% ± 0.3% and 7.4% ± 2.5% depending on the presence of mild or greater aortic valve dysfunction at baseline (P < .01). In multivariable analyses, aortic valve peak pressure gradient (odds ratio, 1.14; 95% confidence interval, 1.10-1.20), aortic regurgitation degree (mild over none: odds ratio, 3.26; 95% confidence interval, 1.15-9.23), and time (odds ratio, 1.30; 95% confidence interval 1.19-1.41) were significantly associated with the occurrence of the primary end point.ConclusionsProgression of severe aortic valve dysfunction and the need for aortic valve replacement are uncommon in patients undergoing rheumatic mitral valve surgery. However, such events were relatively common among those with mild or greater aortic valve dysfunction at the time of mitral valve surgery. 相似文献
5.
6.
7.
8.
《Transfusion and apheresis science》2022,61(1):103366
ObjectiveThere is a paucity of data concerning the use of granulocyte colony-stimulating factors (G-CSFs) in pediatric patients with acute lymphoblastic leukemia (ALL). The aim of the present study was to evaluate the effect of G-CSF use on relapse-free and overall survival in 358 consecutive, newly diagnosed pediatric ALL patients uniformly treated at the same institution between April 2012 and April 2020.Materials and MethodsPatients were evaluated in two separate periods, based on the G-CSF treatment approach. All patients who underwent ALL treatment between April 2012 and December 2016 received G-CSF (G-CSF+ arm; n: 245) in the course of the protocol for reducing the risk of febrile neutropenia and/or inducing neutrophil recovery to prevent any treatment delay. No patients after December 2016 received G-CSF, even if they belonged to the high-risk group, and these were included in the G-CSF? arm (n: 113).ResultsEstimated mean relapse-free (106.5 months; 95 % CI 102?110.8 vs 82 months 95 % CI 75.2?88.9; p: 0.794) and overall survival (111.4 months; 95 % CI 108?114.8 vs 85 months 95 % CI 80.4?89.8; p: 0.431) rates were similar between the G-CSF+ and G-CSF? groups.ConclusionsOur findings indicate that G-CSF use during ALL treatment had no effect on relapse rates or overall survival. 相似文献
9.
目的 探讨血液肿瘤患者接受化疗后发生肛周感染的危险因素。方法 采用回顾性病例对照研究的方法,对四川省某三级甲等医院血液内科2020年12月—2021年5月收治的进行化疗的348例血液肿瘤住院患者相关资料(人口学特征、疾病特征、医疗及护理病例记录、实验室检查结果)予以回顾性分析,根据出院诊断发生肛周感染的病例作为病例组,其余病例作为对照组,统计血液肿瘤患者接受化疗后肛周感染的发生率,采用单因素分析和二元Logistic回归分析肛周感染的危险因素。结果 348例血液肿瘤化疗患者,发生肛周感染35例,感染率为10.1%;Logistic回归分析显示,年龄<60岁(OR=8.776,P=0.039)、痔疮史(OR=7.733,P<0.001)、肛周感染史(OR=14.981,P<0.001)、腹泻(OR=3.893,P=0.019)及白细胞计数<1×109/L(OR=6.851,P=0.002)是血液肿瘤患者接受化疗后发生肛周感染的独立危险因素。结论 血液肿瘤患者接受化疗后肛周感染的发生率较高,年龄<60岁、痔疮史、肛周感染史、腹泻、白细胞计数<1×109/L导致血液肿瘤化疗患者肛周感染率增加,在护理化疗期的血液肿瘤患者过程中,应该结合肛周感染的危险因素,采取针对性干预措施,降低肛周感染发生率。 相似文献
10.
《Vaccine》2022,40(19):2679-2695
Vaccinations are essential for preventing infectious diseases in children with chronic diseases as they have increased risk of infection from frequent use of biologics. Response to immunizations in this group is not well known.ObjectiveA systematic review was performed to evaluate three primary outcomes: efficacy; immunogenicity; and safety of vaccines in children with chronic conditions treated with biologics.MethodsThe protocol for our systematic review and meta-analysis was registered and published with PROSPERO. We searched electronic bibliographic databases for studies published from 2009 to 2019, focusing on vaccinations in children with chronic conditions treated with biologics.ResultsWe retrieved 532 records. Thirty-one full-text articles were selected, and 14 were included in the meta-analysis. No significant publication bias was found. Efficacy: limited data are available regarding the efficacy of vaccination, as most studies have focused on immunogenicity as surrogate outcome for efficacy. Immunogenicity: patients receiving anti-TNF-alpha therapy had a statistically significant risk of poor seroconversion (p = 0.028) and seroprotection by the serotype B influenza vaccine [inflammatory bowel disease (IBD) p = 0.013; juvenile idiopathic arthritis (JIA) p = 0.004]. We found adequate responses with H1N1 and H3N2 serotypes. Few studies existed for pneumococcal, hepatitis A virus, hepatitis B virus, varicella-zoster virus, Measles Mumps Rubella virus, and multiple vaccine administration. Safety: vaccine administration was not associated with serious side effects, but JIA patients on anti-TNF alpha therapy had a statistically significant risk of presenting with myalgia or arthralgia postinfluenza vaccine (p = 0.014).ConclusionsMore evidence concerning efficacy, immunogenicity, and safety of vaccinations is needed to guide physicians in the vaccine decision process for this pediatric population. 相似文献